Sohu.com Limited - American Depositary Shares (SOHU)
14.16
-0.27 (-1.87%)
Sohu.com Inc is a Chinese online media, game, and search services company that provides a variety of internet-related content and services
It operates several platforms, including a prominent web portal that offers news, entertainment, and lifestyle content. Additionally, the company is involved in online gaming, producing and publishing games that cater to a diverse audience. Sohu also provides search engine services, allowing users to access information and resources efficiently. Through its various digital properties, Sohu aims to engage users with a comprehensive mix of content and interactive experiences.
Chinese internet company Sohu.com reports 13% Y/Y revenue growth, but adjusted loss per ADS increases. Expects decline in brand advertising and online game revenues.
Sohu.com reported a 14% revenue decline YoY in Q1 2024, with a net loss of $(0.65) per ADS. The company expects a decrease in brand advertising revenue for Q2.
As of April 8, 2024, four stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Sohu.com Limited (NASDAQ: SOHU) reported a revenue decline of 22% year-over-year to $145.4 million for the third quarter of 2023. Revenue was down by 4% Q/Q.
Sohu.com Limited (NASDAQ: SOHU) reported a revenue decline of 22% year-over-year to $152.1 million for the second-quarter of 2023, missing the consensus of $153.7 million.
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. HUTCHMED (China) Limited (NYSE: HCM) shares dipped 14.1% to $14.06 in pre-market.
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
